Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control regimen Clear all

Conditions: Postoperative Pain
Interventions: Subpleural pain catheter with infusion of 0.125% bupivacaine, Standard acute pain management; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: MAC Lung Disease, Treatment Refractory MAC Lung Disease
Interventions: Epetraborole, Placebo; Drug
Lead sponsor: AN2 Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 49
States / cities: Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 39 more

Conditions: Patent Ductus Arteriosus, Preterm Infant, Bronchopulmonary Dysplasia
Interventions: Ibuprofen and acetaminophen, Ibuprofen and placebo; Drug
Lead sponsor: University of South Alabama; Other
Eligibility: 5 Days to 21 Days
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Mobile, Alabama

Conditions: Infectious Pneumonia, Severe COVID-19
Interventions: Reparixin, Placebo; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years and older
Enrollment: 414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 28
States / cities: Tucson, Arizona • Orange, California • Denver, Colorado + 24 more

Conditions: Adenotonsillectomy, Analgesia, Surgery
Interventions: Dexamethasone, Ibuprofen, Acetaminophen, Placebo; Drug
Lead sponsor: David Chi, MD; Other
Eligibility: 3 Years to 17 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Sewickley, Pennsylvania

Conditions: Kidney Transplant; Complications, Kidney Transplant Failure and Rejection
Interventions: Envarsus, Tacrolimus; Drug
Lead sponsor: California Institute of Renal Research; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Geriatric Hip Fracture
Interventions: XR™ Recovery Supplement, XR Carbohydrate Loading Supplement; Dietary Supplement
Lead sponsor: NYU Langone Health; Other
Eligibility: 65 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Kidney Failure
Interventions: Tacrolimus, Everolimus; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 1,541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 82
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 67 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: COYA 302, Placebo; Drug
Lead sponsor: Coya Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more

Conditions: Ametropia
Interventions: VISA (comfilcon A) Silicone Hydrogel Soft contact lens, Acuvue 2 Soft Contact Lens; Device
Lead sponsor: CooperVision, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 23
States / cities: La Mesa, California • San Diego, California • Santa Monica, California + 17 more

Conditions: Diabetes Mellitus Type I, Diabetes Mellitus Type II
Interventions: EHR Based Strategy to promote Safe and Appropriate Drug Use; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Acute Otitis Media
Interventions: AR01, Glycerin ear drops; Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 2 Months to 18 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 29
States / cities: Sheffield, Alabama • Tuscon, Arizona • Jonesboro, Arkansas + 25 more

Conditions: Veterans, Tobacco Use Disorder, Cigarette Smoking, Tobacco Dependence
Interventions: Motivation-Phase Varenicline, Motivation-Phase Nicotine Mini-Lozenge, Cessation-Phase Combination Nicotine Replacement Therapy (NRT), Cessation-Phase Varenicline, Motivation-Phase Counseling, Cessation-Phase Counseling; Drug · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: San Diego, California • Minneapolis, Minnesota • Durham, North Carolina + 1 more

Conditions: Rheumatoid Arthritis
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 12
States / cities: Anniston, Alabama • Birmingham, Alabama • Peoria, Arizona + 8 more

Conditions: Skin
Interventions: Fasting mimicking diet (FMD); Other
Lead sponsor: L-Nutra Inc; Industry
Eligibility: 35 Years to 60 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: Diabetes Mellitus
Interventions: Insulin Lispro, Exubera; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 62
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more

Conditions: Epilepsy, Complex Partial
Interventions: ganaxolone; Drug
Lead sponsor: Marinus Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 7
States / cities: Los Angeles, California • Lexington, Kentucky • Albany, New York + 3 more

Conditions: Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease
Interventions: AADvac1, Tau2; Drug
Lead sponsor: Paul S. Aisen; Other
Eligibility: 50 Years to 80 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Phoenix, Arizona • San Francisco, California • Lexington, Kentucky + 4 more

Conditions: Cardiovascular Events
Interventions: Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo for Aliskiren, Placebo for Amlodipine, Placebo for Hydrochlorothiazide (HCTZ); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 65 Years and older
Enrollment: 2,336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Northridge, California + 11 more

Conditions: Type 2 Diabetes, Vitamin D Deficiency
Interventions: Vitamin D2, Sugar pill; Dietary Supplement · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 12 Years to 18 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Turner Syndrome
Interventions: somatotropin; Drug
Lead sponsor: Rebecca Knickmeyer Santelli, PhD; Other
Eligibility: 11 Months to 13 Months · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Metastatic Colorectal Cancer
Interventions: 5-Fluorouracil, Bevacizumab, Folinic acid, MEGF0444A, Oxaliplatin, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 23
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 18 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, Lispro Low Mix, Lispro Mid Mix, Lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 30 Years to 79 Years
Enrollment: 2,091 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 138
States / cities: Mobile, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 135 more

Search by objective public record fields.

Continuous Subpleural Infusion of Bupivacaine

Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

Randomized Controlled Trial to Evaluate the Safety and Efficacy of Acetaminophen in Preterm Infants Used in Combination With Ibuprofen for Closure of the Ductus Arteriosus

Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Post-operative Course of Dexamethasone to Reduce Tonsillectomy Morbidity

Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients

Nutritional Supplementation in Geriatric Hip Fractures

Everolimus Monotherapy as Immunosuppression After Liver Transplant

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

Study of COYA 302 for the Treatment of ALS

Study of Soft Contact Lens Use With 7 Day Extended Wear

A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use

Phase 3 Study to Compare the Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media

Varenicline for Smoking Reduction in Veterans Not Ready To Quit

Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis

Effect of Fasting-Mimicking Diet on Skin Health

Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes

A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601

Alzheimer's Tau Platform: Master Protocol

A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People

African American Children, Glycemic Control, and Type 2 Diabetes

Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome

A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)